Andrew Farb, M.D. is the Chief Medical Officer in the Office of Cardiovascular Devices at FDA’s Center for Devices and Radiological Health (CDRH). He is a graduate of Dartmouth College (B.A.) and Cornell University Medical College (M.D.). He completed an internship and residency in internal medicine, a one-year residency in anatomic pathology, and a fellowship in clinical cardiology at The New York Hospital – Cornell University Medical Center. Andrew is board-certified in Internal Medicine and Cardiovascular Diseases. Following a fellowship in cardiovascular pathology at The Armed Forces Institute of Pathology (AFIP), he served as a staff cardiovascular pathologist at AFIP with research interests in and multiple publications on coronary atherosclerosis and mechanisms of thrombosis, coronary artery interventions, and structural heart disease. He joined the FDA in 2004, where he has concentrated on clinical study development for interventional cardiology, structural heart, and peripheral vascular devices as well as providing guidance on non-clinical animal testing. Since 2013, Andrew has focused on regulatory approaches to facilitating medical device innovation and early stage medical device studies in the US. He co-authored FDA’s Guidance document entitled “Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies, Including Certain First in Human (FIH) Studies,” and he is the Co-Leader of CDRH’s Early Feasibility Study Program.

In the field of atrial fibrillation, Andrew has served as the lead FDA clinical reviewer for medical devices designed to close the heart’s left atrial appendage. In addition to his position at FDA, Andrew provides cardiovascular pathology consultations and engages in direct patient care as an attending physician in clinical cardiology.